» Articles » PMID: 7971718

Uptake of Nanoparticles by Rat Glomerular Mesangial Cells in Vivo and in Vitro

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 1994 Aug 1
PMID 7971718
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Glomerular mesangial cells play a major role in the structure of capillary loops, generation of mediators of inflammation, and uptake of macromolecules. We demonstrate here that isobutylcyanoacrylate nanoparticles loaded with actinomycin D (ADNP) concentrate in rat mesangial cells in vitro and in vivo, as compared to the free drug (AD). In normal rats injected with 20 micrograms of 3H-ADNP or 3H-AD, the uptake ratios 3H-ADNP/3H-AD measured in whole kidneys at 30 and 120 min were 2.2 +/- 1.0 and 2.3 +/- 0.9, respectively. The same ratios calculated for isolated rat glomeruli and tubules, were 4.1 +/- 0.5 and 0.8 +/- 0.2 at 30 min, and 2.6 +/- 0.5 and 0.6 +/- 0.3 at 120 min, respectively. In the glomeruli, the absolute uptake of 3H-ADNP corresponded to 7.5 (30 min) and 1.8 (120 min)% I.D./100 mg of protein. In rats with experimental glomerulonephritis, the uptakes of 3H-ADNP and 3H-AD by the glomeruli were 6.9 and 4.0 times higher than in normal rats, respectively. In vitro experiments demonstrated up to 5 times higher uptake by glomerular mesangial cells than by epithelial cells. Uptake was maximum after 60 min, higher at 37 degrees C than at 4 degrees C, dependent on the presence of fresh serum and inhibited by cytochalasin-B. Drug targeting by nanoparticles is thus possible to renal cells involved in inflammatory processes, especially mesangial cells and macrophages. Nanoparticles could also be useful for lowering drug concentration in tubular cells, to reduce any tubular toxicity.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Nanomaterials for targeted therapy of kidney diseases: Strategies and advances.

Wang Z, Zhang C Mater Today Bio. 2025; 31:101534.

PMID: 39990736 PMC: 11846943. DOI: 10.1016/j.mtbio.2025.101534.


Surface coating determines the inflammatory potential of magnetite nanoparticles in murine renal podocytes and mesangial cells.

Selc M, Razga F, Nemethova V, Mazancova P, Ursinyova M, Novotova M RSC Adv. 2022; 10(40):23916-23929.

PMID: 35517346 PMC: 9055089. DOI: 10.1039/d0ra03133j.


Application of Advanced Nanomaterials for Kidney Failure Treatment and Regeneration.

Eftekhari A, Dizaj S, Ahmadian E, Przekora A, Hosseiniyan Khatibi S, Ardalan M Materials (Basel). 2021; 14(11).

PMID: 34072461 PMC: 8198057. DOI: 10.3390/ma14112939.


Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.

Pranatharthiharan S, Patel M, Malshe V, Pujari V, Gorakshakar A, Madkaikar M Drug Deliv. 2017; 24(1):20-29.

PMID: 28155331 PMC: 8244555. DOI: 10.1080/10717544.2016.1225856.


A kidney-selective biopolymer for targeted drug delivery.

Bidwell 3rd G, Mahdi F, Shao Q, Logue O, Waller J, Reese C Am J Physiol Renal Physiol. 2016; 312(1):F54-F64.

PMID: 27784692 PMC: 5283886. DOI: 10.1152/ajprenal.00143.2016.


References
1.
Cuvier C, Millot J, Lizard G, Chevillard S, Manfait M, Couvreur P . Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharmacol. 1992; 44(3):509-17. DOI: 10.1016/0006-2952(92)90443-m. View

2.
Lovett D, Sterzel R . Cell culture approaches to the analysis of glomerular inflammation. Kidney Int. 1986; 30(2):246-54. DOI: 10.1038/ki.1986.176. View

3.
Manil L, Couvreur P . Isobutyl cyanoacrylate nanoparticles as a solid phase for an efficient immunoradiometric assay. Biomaterials. 1986; 7(3):212-6. DOI: 10.1016/0142-9612(86)90105-5. View

4.
Couvreur P, Kante B, Roland M, SPEISER P . Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum. J Pharm Sci. 1979; 68(12):1521-4. DOI: 10.1002/jps.2600681215. View

5.
Couvreur P, Kante B, Grislain L, Roland M, SPEISER P . Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles. J Pharm Sci. 1982; 71(7):790-2. DOI: 10.1002/jps.2600710717. View